Your browser doesn't support javascript.
Clinical risk factors of adverse outcomes among women with COVID-19 in the pregnancy and postpartum period: A sequential, prospective meta-analysis.
Smith, Emily R; Oakley, Erin; Grandner, Gargi Wable; Rukundo, Gordon; Farooq, Fouzia; Ferguson, Kacey; Baumann, Sasha; Waldorf, Kristina Adams; Afshar, Yalda; Ahlberg, Mia; Ahmadzia, Homa; Akelo, Victor; Aldrovandi, Grace; Bevilacqua, Elisa; Bracero, Nabal; Brandt, Justin S; Broutet, Natalie; Carrillo, Jorge; Conry, Jeanne; Cosmi, Erich; Crispi, Fatima; Crovetto, Francesca; Gil, Maria Del Mar; Delgado-López, Camille; Divakar, Hema; Driscoll, Amanda J; Favre, Guillaume; Buhigas, Irene Fernandez; Flaherman, Valerie; Gale, Christopher; Godwin, Christine L; Gottlieb, Sami; Gratacós, Eduard; He, Siran; Hernandez, Olivia; Jones, Stephanie; Joshi, Sheetal; Kalafat, Erkan; Khagayi, Sammy; Knight, Marian; Kotloff, Karen; Lanzone, Antonio; Longo, Valentina Laurita; Le Doare, Kirsty; Lees, Christoph; Litman, Ethan; Lokken, Erica M; Madhi, Shabir A; Magee, Laura A; Martinez-Portilla, Raigam Jafet.
  • Smith ER; Department of Global Health, George Washington University Milken Institute School of Public Health, Washington, DC, USA.
  • Oakley E; Department of Global Health, George Washington University Milken Institute School of Public Health, Washington, DC, USA.
  • Grandner GW; Department of Global Health, George Washington University Milken Institute School of Public Health, Washington, DC, USA.
  • Rukundo G; PeriCovid (PREPARE) - Uganda Team, Makerere University - Johns Hopkins University Research Collaboration, Uganda.
  • Farooq F; Department of Global Health, George Washington University Milken Institute School of Public Health, Washington, DC, USA.
  • Ferguson K; Department of Global Health, George Washington University Milken Institute School of Public Health, Washington, DC, USA.
  • Baumann S; Department of Global Health, George Washington University Milken Institute School of Public Health, Washington, DC, USA.
  • Waldorf KA; Department of Obstetrics and Gynecology, School of Medicine, University of Washington, USA; Department of Global Health, University of Washington, Washington, USA.
  • Afshar Y; Division of Maternal Fetal Medicine, University of California Los Angeles, Los Angeles, CA, United States.
  • Ahlberg M; Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
  • Ahmadzia H; Division of Maternal-Fetal Medicine, The George Washington University School of Medicine and Health Sciences.
  • Akelo V; US Centers for Disease Control and Prevention, Kisumu, Kenya.
  • Aldrovandi G; Department of Pediatrics, University of California Los Angeles, Los Angeles, CA, USA.
  • Bevilacqua E; Department of Women and Child Health, Women Health Area, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.
  • Bracero N; University of Puerto Rico School of Medicine, Department of Obstetrics and Gynecology; Puerto Rico Obstetrics and Gynecology (PROGyn).
  • Brandt JS; Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
  • Broutet N; Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
  • Carrillo J; Departmento de Obstetricia y Ginecologia, Clinica Alemana de Santiago, Facultad de Medicina Clinica Alemana-Universidad del Desarrollo, Santiago, Chile.
  • Conry J; OBGYN, The International Federation of Gynecology and Obstetrics, London, United Kingdom.
  • Cosmi E; Department of Woman's and Child's Health, Obstetrics and Gynecologic Clinic, University of Padua, Padua, Italy.
  • Crispi F; BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clínic, Universitat de Barcelona, and Center for Biomedical Research on Rare Diseases, CIBER-ER, Barcelona, Spain.
  • Crovetto F; BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clínic, Universitat de Barcelona, and Center for Biomedical Research on Rare Diseases, CIBER-ER, Barcelona, Spain.
  • Gil MDM; Department of Obstetrics and Gynecology, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain; School of Medicine, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain.
  • Delgado-López C; Surveillance for Emerging Threats to Mothers and Babies, Puerto Rico Department of Health, San Juan, Puerto Rico.
  • Divakar H; Asian Research and Training Institute for Skill Transfer (ARTIST), Bengaluru, India.
  • Driscoll AJ; Center for Vaccine Development and Global Health, University of Maryland, School of Medicine, Baltimore, MD, USA.
  • Favre G; Materno-fetal and Obstetrics Research Unit, Department "Femme-Mère-Enfant", University Hospital, Lausanne, Switzerland.
  • Buhigas IF; Department of Obstetrics and Gynecology, Hospital Universitario de Torrejón, Torrejón de Ardoz, Madrid, Spain; School of Medicine, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain.
  • Flaherman V; Department of Pediatrics, University of California San Francisco, CA, San Francisco, USA.
  • Gale C; Neonatal Medicine, School of Public Health, Faculty of Medicine, Imperial College London, United Kingdom.
  • Godwin CL; Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
  • Gottlieb S; Department of Sexual and Reproductive Health and Research, World Health Organization, Geneva, Switzerland.
  • Gratacós E; BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Sant Joan de Déu and Hospital Clínic, Universitat de Barcelona, and Center for Biomedical Research on Rare Diseases, CIBER-ER, Barcelona, Spain.
  • He S; Department of Global Health, George Washington University Milken Institute School of Public Health, Washington, DC, USA.
  • Hernandez O; Gynecology and Obstetrics, Felix Bulnes Hospital and RedSalud Clinic, Santiago, Chile.
  • Jones S; South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, and Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Disease
  • Joshi S; Asian Research and Training Institute for Skill Transfer (ARTIST), Bengaluru, India.
  • Kalafat E; Department of Obstetrics and Gynecology, School of Medicine, Koc University, Istanbul, Turkey.
  • Khagayi S; Kenya Medical Research Institute-Center for Global Health Research, Kisumu Kenya.
  • Knight M; National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
  • Kotloff K; Center for Vaccine Development and Global Health, University of Maryland, School of Medicine, Baltimore, MD, USA.
  • Lanzone A; Department of Women and Child Health, Women Health Area, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; Catholic University of Sacred Hearth, Rome, Italy.
  • Longo VL; Department of Women and Child Health, Women Health Area, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; Catholic University of Sacred Hearth, Rome, Italy.
  • Le Doare K; PeriCovid (PREPARE) - Uganda Team, Makerere University - Johns Hopkins University Research Collaboration, Uganda; Medical Research Council /Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit, Entebbe, Uganda; Pediatric Infectious Diseases Resear
  • Lees C; Department of Metabolism, Digestion, and Reproduction, Imperial College London, United Kingdom.
  • Litman E; Division of Maternal-Fetal Medicine, The George Washington University School of Medicine and Health Sciences.
  • Lokken EM; Department of Obstetrics and Gynecology, School of Medicine, University of Washington, USA; Department of Global Health, University of Washington, Washington, USA.
  • Madhi SA; South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, and Department of Science and Technology/National Research Foundation, South African Research Chair Initiative in Vaccine Preventable Disease
  • Magee LA; Department of Women and Children's Health, School of Life Course Sciences, King's College London, United Kingdom; Institute of Women and Children's Health, King's College Hospital, London, UK.
  • Martinez-Portilla RJ; Clinical Research Branch, National Institute of Perinatology, Mexico City, Mexico.
Am J Obstet Gynecol ; 2022 Aug 23.
Article in English | MEDLINE | ID: covidwho-2235755
ABSTRACT

OBJECTIVE:

This sequential, prospective meta-analysis (sPMA) sought to identify risk factors among pregnant and postpartum women with COVID-19 for adverse outcomes related to disease severity, maternal morbidities, neonatal mortality and morbidity, adverse birth outcomes. DATA SOURCES We prospectively invited study investigators to join the sPMA via professional research networks beginning in March 2020. STUDY ELIGIBILITY CRITERIA Eligible studies included those recruiting at least 25 consecutive cases of COVID-19 in pregnancy within a defined catchment area. STUDY APPRAISAL AND SYNTHESIS

METHODS:

We included individual patient data from 21 participating studies. Data quality was assessed, and harmonized variables for risk factors and outcomes were constructed. Duplicate cases were removed. Pooled estimates for the absolute and relative risk of adverse outcomes comparing those with and without each risk factor were generated using a two-stage meta-analysis.

RESULTS:

We collected data from 33 countries and territories, including 21,977 cases of SARS-CoV-2 infection in pregnancy or postpartum. We found that women with comorbidities (pre-existing diabetes, hypertension, cardiovascular disease) versus those without were at higher risk for COVID-19 severity and pregnancy health outcomes (fetal death, preterm birth, low birthweight). Participants with COVID-19 and HIV were 1.74 times (95% CI 1.12, 2.71) more likely to be admitted to the ICU. Pregnant women who were underweight before pregnancy were at higher risk of ICU admission (RR 5.53, 95% CI 2.27, 13.44), ventilation (RR 9.36, 95% CI 3.87, 22.63), and pregnancy-related death (RR 14.10, 95% CI 2.83, 70.36). Pre-pregnancy obesity was also a risk factor for severe COVID-19 outcomes including ICU admission (RR 1.81, 95% CI 1.26,2.60), ventilation (RR 2.05, 95% CI 1.20,3.51), any critical care (RR 1.89, 95% CI 1.28,2.77), and pneumonia (RR 1.66, 95% CI 1.18,2.33). Anemic pregnant women with COVID-19 also had increased risk of ICU admission (RR 1.63, 95% CI 1.25, 2.11) and death (RR 2.36, 95% CI 1.15, 4.81).

CONCLUSION:

We found that pregnant women with comorbidities including diabetes, hypertension, and cardiovascular disease were at increased risk for severe COVID-19-related outcomes, maternal morbidities, and adverse birth outcomes. We also identified several less commonly-known risk factors, including HIV infection, pre-pregnancy underweight, and anemia. Although pregnant women are already considered a high-risk population, special priority for prevention and treatment should be given to pregnant women with these additional risk factors.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study / Reviews Language: English Year: 2022 Document Type: Article Affiliation country: J.ajog.2022.08.038

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study / Reviews Language: English Year: 2022 Document Type: Article Affiliation country: J.ajog.2022.08.038